Compare ROIV & TECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROIV | TECK |
|---|---|---|
| Founded | 2014 | 1913 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 32.4B |
| IPO Year | 2021 | 1997 |
| Metric | ROIV | TECK |
|---|---|---|
| Price | $38.91 | $48.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 17 |
| Target Price | $50.82 | ★ $60.84 |
| AVG Volume (30 Days) | ★ 7.1M | 2.9M |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 0.70% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,260,000.00 | N/A |
| Revenue This Year | $1,870.25 | $45.29 |
| Revenue Next Year | $271.46 | $1.64 |
| P/E Ratio | ★ N/A | $32.94 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.96 | $39.51 |
| 52 Week High | $42.50 | $72.56 |
| Indicator | ROIV | TECK |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 27.46 |
| Support Level | $33.11 | $48.34 |
| Resistance Level | $42.37 | $67.93 |
| Average True Range (ATR) | 1.55 | 2.18 |
| MACD | -0.07 | -1.27 |
| Stochastic Oscillator | 49.40 | 1.18 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Teck is a base metals miner with copper and zinc operations in Canada, the United States, Chile, and Peru. After selling its metallurgical coal business, copper is now its major commodity by EBITDA contribution, followed by zinc. Teck is a top-three zinc miner. Its major new copper mine in Chile at the majority-owned Quebrada Blanca 2, in partnership with Sumitomo, will drive an increase in Teck's attributable copper production by roughly 80%. Along with a number of additional copper growth options, Teck's strategy is to rebalance its portfolio to low-carbon metals such as copper. It sold its oil sands business in early 2023 and its coal business in mid-2024. In September 2025, it agreed to merge with Anglo American in an all-equity deal.